Eli Lilly reports fiscal Q1 2026 results: revenue $19.80B, up 56% from a year earlier

Eli Lilly filed a Form 8-K with the SEC on Apr 30, 2026, 7:03 AM ET, reporting an event dated Apr 30, 2026. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q1 2026 (quarter ended Mar 31, 2026); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $19.80B (+55.5% from $12.73B a year earlier)
• Net income: $7.40B (+168.1% from $2.76B a year earlier)
• Diluted EPS: $8.26 (+169.9% from $3.06 a year earlier)
• Form 8-K accepted by EDGAR Apr 30, 2026, 7:03 AM ET
• Accession number 0000059478-26-000043

SEC filing 8-K · accession 0000059478-26-000043 · sec.gov ↗